🇺🇸 FDA
Patent

US 9622983

Sustained-release formulations of topiramate

granted A61KA61K31/357A61K31/7048

Quick answer

US patent 9622983 (Sustained-release formulations of topiramate) held by Supernus Pharmaceuticals, Inc. expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Supernus Pharmaceuticals, Inc.
Grant date
Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/357, A61K31/7048, A61K45/06, A61K47/6951